XBI ETF holdings (NYSE) - Page 5 | MetaTrader

Abrir gráfico completo Full chart

Visão geral Todos os ativos Mapa de calor

Principais ativos Market Value Shares Weight %

DNTH Dianthus Therapeutics Inc 39.5 M 958.9 K 0.5%

BHVN Biohaven Ltd 39.2 M 3.5 M 0.5%

ARDX Ardelyx Inc 37.7 M 6.5 M 0.5%

RCUS Arcus Biosciences Inc 36.7 M 1.5 M 0.5%

NVAX Novavax Inc 36.7 M 5.5 M 0.5%

TNGX Tango Therapeutics Inc 33.3 M 3.8 M 0.4%

KURA Kura Oncology Inc 32.3 M 3.1 M 0.4%

NTLA Intellia Therapeutics Inc 32.1 M 3.6 M 0.4%

IOVA Iovance Biotherapeutics Inc 32.0 M 11.7 M 0.4%

TSHA Taysha Gene Therapies Inc 31.4 M 5.7 M 0.4%

RIGL Rigel Pharmaceuticals Inc 30.6 M 714.1 K 0.4%

SYRE Spyre Therapeutics Inc 29.0 M 884.9 K 0.4%

NRIX Nurix Therapeutics Inc 28.5 M 1.5 M 0.4%

CDNA CareDx Inc 28.4 M 1.5 M 0.4%

ANAB AnaptysBio Inc 28.4 M 585.1 K 0.4%

KOD Kodiak Sciences Inc 27.6 M 986.2 K 0.4%

PVLA Palvella Therapeutics Inc 27.3 M 260.7 K 0.3%

RLAY Relay Therapeutics Inc 27.2 M 3.2 M 0.3%

PGEN Precigen Inc 25.9 M 6.2 M 0.3%

XNCR Xencor Inc 24.8 M 1.6 M 0.3%

1
2
3
4
5
6
7
8

Notícias

First Quarter Earnings: Sharpening Sector Divergence

Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

3 Reasons To Stick With Growth Stocks In Rotating Markets

Seeking Innovation Beyond Tech? Insight On Healthcare Stocks

Biotech Investors Are Tuning Out the MAHA Chaos

Makary's Successor Faces Tough Task Managing FDA Amid Budget Cuts

Maravai LifeSciences: Better Earnings Drive Gains That Ought To Be Sustainable (MRVI)

Preço-alvo da Capricor mantido em US$ 63 pela B.Riley com avanços na FDA

FDA Commissioner Marty Makary Expected To Resign, Ending Turbulent Stint

Why I Now Favor A Barbell Model Over Ray Dalio’s All-Weather Portfolio (SPY)

Juros a descoberto da Intellia lideram alta entre biotechs, diz Baird

Mizuho reduz preço-alvo da Immunocore para US$ 34 após revisão de receita